Metformin and Testosterone in Men: Does It Lower T?

Metformin is the most widely prescribed drug for type 2 diabetes, working mainly by reducing glucose production in the liver and improving insulin sensitivity. Whether it lowers testosterone is not settled. In a secondary analysis of a real-world study of men aged 18 to 60 with type 2 diabetes treated with insulin, total and bioavailable testosterone fell over 3 months in men taking metformin, while they rose in matched men not taking it [1]. That is a small observational analysis and does not show that metformin causes low testosterone: obesity and diabetes are themselves associated with lower testosterone, and that suppression may be reversible [2]. Men with diabetes and symptoms of low testosterone should ask their doctor about testing, since low testosterone is diagnosed from repeated morning measurements [3].

Should This Change Whether You Take Metformin? Short Answer

No, not on its own — this is worth stating plainly before working through the mechanism details, because the evidence for a testosterone-lowering effect, while biologically real, is genuinely mixed in its clinical magnitude and dwarfed by the well-established benefits of metformin for diabetes management. Uncontrolled or poorly controlled type 2 diabetes is itself a strong, well-documented cause of low testosterone through direct suppression of the hypothalamic-pituitary-gonadal axis, meaning stopping metformin and allowing blood sugar to worsen would very plausibly make testosterone worse, not better, even if metformin does have a modest direct suppressive effect on Leydig cells. The right response to concern about metformin and testosterone isn't to stop the medication, but to add testosterone monitoring to the existing diabetes management plan and address it as a parallel issue — treating both diabetes and any confirmed low testosterone together rather than treating them as competing priorities.

Mechanism: How Metformin May Lower Testosterone

• •AMPK activation in Leydig cells: metformin activates AMP-activated protein kinase in Leydig cells → reduces StAR (steroidogenic acute regulatory protein) expression → impairs cholesterol transport into mitochondria → reduces testosterone synthesis
• •Reduced LH sensitivity: AMPK activation may reduce cAMP generation in response to LH stimulation → blunted Leydig cell response
• •Indirect: metformin improves insulin sensitivity → reduces hyperinsulinism-driven aromatase activity → this effect may paradoxically improve testosterone in very obese insulin-resistant men
• •Net effect: unclear; one small study found lower testosterone with metformin [1], and diabetes and obesity are themselves linked to lower testosterone [2]
• •Sperm effects: metformin may reduce sperm motility via AMPK activation in spermatozoa — relevant for men with fertility concerns

Clinical Recommendations for Men on Metformin

• •Monitor testosterone: men on metformin with symptoms of low T (fatigue, reduced libido, ED) should have testosterone panel checked
• •Do not stop metformin based on T concern alone: diabetes management benefit outweighs theoretical T reduction risk; work with endocrinologist
• •Consider alternatives: GLP-1 agonists (semaglutide, liraglutide) do not impair testosterone and provide significant weight loss benefit — may be preferable in obese men with concurrent low T
• •Address underlying diabetes effect: poorly controlled diabetes independently causes testosterone deficiency via HPG suppression; improving glycemic control often improves T
• •SGLT2 inhibitors: some evidence that SGLT2 inhibitors (empagliflozin, dapagliflozin) may positively affect testosterone — alternative for men with metformin-associated T concerns

Untangling Diabetes-Related Low T From Metformin-Related Low T

One of the genuinely tricky parts of this picture is that men taking metformin already have type 2 diabetes, a condition independently and strongly associated with low testosterone through multiple pathways — chronic inflammation, insulin resistance affecting the HPG axis, and often coexisting obesity driving increased aromatase activity. This means a diabetic man on metformin with low testosterone has at least two, and often three, plausible contributing factors happening simultaneously, making it genuinely difficult to attribute the low T specifically to the medication versus the underlying disease versus body composition. In practice, this distinction matters less for treatment decisions than it might seem — regardless of which factor is dominant, the management approach (confirm with blood testing, optimize glycemic control, address weight if relevant, consider TRT if truly hypogonadal and symptomatic) is largely the same. Where the distinction matters more is in expectation-setting: a man whose low T improves substantially once his diabetes is better controlled has good evidence the diabetes itself was the primary driver, while persistent low T despite excellent glycemic control points more toward either the medication or an independent hypogonadism unrelated to diabetes.

The Broader Context: Diabetes Drugs and Hormonal Health

Metformin's relationship with testosterone is a useful example of a broader principle worth understanding for any man managing a chronic condition alongside hormonal health concerns: medications are rarely hormonally neutral, and the diabetes drug landscape specifically has meaningfully different hormonal profiles across drug classes. This doesn't mean every diabetic man needs to switch medications reactively based on theoretical hormonal concerns, but it does mean that when working with an endocrinologist on both diabetes and testosterone management simultaneously, it's worth having an explicit conversation about the full medication regimen's hormonal effects rather than treating diabetes management and hormonal health as entirely separate conversations happening with different specialists who aren't necessarily coordinating. A man managing both conditions well is often best served by a single endocrinologist or a closely coordinated care team who can weigh glycemic control, cardiovascular risk, weight management, and hormonal health together rather than optimizing each in isolation.